tbuckley/cabot-search huggingface dataset:
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation—Reply
Authors: Wayne A. Ray, Katherine T. Murray
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Imaging Aldosterone-Producing Adrenocortical Carcinoma With 68Ga-Pentixafor PET/CT
Authors: QiaoQiao Shu, Maoxue Deng, Yue Chen, Nan Liu, Liang Cai
Journal: Clinical Nuclear Medicine (2022)

Chemokine receptor 4 (CXCR4) is a 7-transmembrane G protein-coupled receptor, and pentixafor is considered to be a potent ligand for the CXCR4 receptor. Recently, 68 Ga-pentixafor has been reported as a potential PET imaging agent for CXCR4-positive tumors and inflammatory lesions, including adrenocortical lesions. We report a case of primary aldosteronism due to adrenocortical carcinoma with intense 68 Ga-pentixafor activity on PET/CT.
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study
Authors: Maud Lemoine, Lambert Assoumou, Pierre-Marie Girard, Marc Antoine Valantin, Christine Katlama, Stephane De Wit, Pauline Campa, Hayette Rougier, Jean-Luc Meynard, Coca Necsoi, Anja D. Huefner, Jan Van Luzen, Julian Schulze zur Wiesch, Jean-Philippe Bastard, Soraya Fellahi, Stefan Mauss, Metodi V. Stankov, Axel Baumgarten, Gerrit Post, Lawrence Serfaty, Vlad Ratziu, Yves Menu, Jerome Schlue, Pierre Bedossa, Jacqueline Capeau, Dominique Costagliola, Georg Behrens, Patrick Ingiliz
Journal: Clinical Gastroenterology and Hepatology (2022)
Ten Years of Choosing Wisely to Reduce Low-Value Care
Authors: Elizabeth J. Rourke
Journal: New England Journal of Medicine (2022)

Interview with Dr. Vikas Saini on the Choosing Wisely campaign and approaches for addressing low-value care. (14:22)Download The Choosing Wisely initiative was a public relations win for the medical profession in 2012: doctors were stepping up to address low value and high costs in medicine. Today, it's clear that making lists and publicizing them are not sufficient to reduce low-value care.
The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease
Authors: Stefano Musardo, Sebastien Therin, Silvia Pelucchi, Laura D’Andrea, Ramona Stringhi, Ana Ribeiro, Annalisa Manca, Claudia Balducci, Jessica Pagano, Carlo Sala, Chiara Verpelli, Valeria Grieco, Valeria Edefonti, Gianluigi Forloni, Fabrizio Gardoni, Giovanni Meli, Daniele Di Marino, Monica Di Luca, Elena Marcello
Journal: Molecular Therapy (2022)

The development of new therapeutic avenues that target the early stages of Alzheimer's disease (AD) is urgently necessary. A disintegrin and metalloproteinase domain 10 (ADAM10) is a sheddase that is involved in dendritic spine shaping and limits the generation of amyloid-β. ADAM10 endocytosis increases in the hippocampus of AD patients, resulting in the decreased postsynaptic localization of the enzyme. To restore this altered pathway, we developed a cell-permeable peptide (PEP3) with a strong safety profile that is able to interfere with ADAM10 endocytosis, upregulating the postsynaptic localization and activity of ADAM10. After extensive validation, experiments in a relevant animal model clarified the optimal timing of the treatment window. PEP3 administration was effective for the rescue of cognitive defects in APP/PS1 mice only if administered at an early disease stage. Increased ADAM10 activity promoted synaptic plasticity, as revealed by changes in the molecular compositions of synapses and the spine morphology. Even though further studies are required to evaluate efficacy and safety issues of long-term administration of PEP3, these results provide preclinical evidence to support the therapeutic potential of PEP3 in AD. The development of new therapeutic avenues that target the early stages of Alzheimer's disease (AD) is urgently necessary. A disintegrin and metalloproteinase domain 10 (ADAM10) is a sheddase that is involved in dendritic spine shaping and limits the generation of amyloid-β. ADAM10 endocytosis increases in the hippocampus of AD patients, resulting in the decreased postsynaptic localization of the enzyme. To restore this altered pathway, we developed a cell-permeable peptide (PEP3) with a strong safety profile that is able to interfere with ADAM10 endocytosis, upregulating the postsynaptic localization and activity of ADAM10. After extensive validation, experiments in a relevant animal model clarified the optimal timing of the treatment window. PEP3 administration was effective for the rescue of cognitive defects in APP/PS1 mice only if administered at an early disease stage. Increased ADAM10 activity promoted synaptic plasticity, as revealed by changes in the molecular compositions of synapses and the spine morphology. Even though further studies are required to evaluate efficacy and safety issues of long-term administration of PEP3, these results provide preclinical evidence to support the therapeutic potential of PEP3 in AD.
Radiation Therapy in Older Adults With Cancer: A Critical Modality in Geriatric Oncology
Authors: Arya Amini, Lucinda Morris, Ethan B. Ludmir, Benjamin Movsas, Reshma Jagsi, Noam A. VanderWalde
Journal: Journal of Clinical Oncology (2022)

Radiation therapy (RT) is a commonly used modality in the treatment of older adults with cancer, and RT represents an attractive oncologic treatment option, providing a noninvasive local therapy with limited systemic side effects. The Journal of Clinical Oncology (JCO) recently published a special series on Geriatric Oncology providing a comprehensive overview of multiple treatment modalities available to older adults with cancer. The purpose of this short review is to highlight the importance of RT in the treatment of older adults and encourage multidisciplinary participation in their care.
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
Authors: Jessica Widdifield, Jeffrey C Kwong, Simon Chen, Lihi Eder, Eric I Benchimol, Gilaad G Kaplan, Carol Hitchon, J Antonio Aviña-Zubieta, Diane Lacaille, Hannah Chung, Sasha Bernatsky
Journal: The Lancet Rheumatology (2022)
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
Authors: Nawid Albinger, Rita Pfeifer, Marcus Nitsche, Sarah Mertlitz, Julia Campe, Katja Stein, Hermann Kreyenberg, Ralf Schubert, Melissa Quadflieg, Dina Schneider, Michael W. M. Kühn, Olaf Penack, Congcong Zhang, Nina Möker, Evelyn Ullrich
Journal: Blood Cancer Journal (2022)

Abstract Acute myeloid leukemia (AML) is a malignant disorder derived from neoplastic myeloid progenitor cells characterized by abnormal proliferation and differentiation. Although novel therapeutics have recently been introduced, AML remains a therapeutic challenge with insufficient cure rates. In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed outstanding clinical activity against B-cell malignancies including acute lymphoblastic leukemia (ALL). However, the application of CAR-T cells appears to be challenging due to the enormous molecular heterogeneity of the disease and potential long-term suppression of hematopoiesis. Here we report on the generation of CD33-targeted CAR-modified natural killer (NK) cells by transduction of blood-derived primary NK cells using baboon envelope pseudotyped lentiviral vectors (BaEV-LVs). Transduced cells displayed stable CAR-expression, unimpeded proliferation, and increased cytotoxic activity against CD33-positive OCI-AML2 and primary AML cells in vitro. Furthermore, CD33-CAR-NK cells strongly reduced leukemic burden and prevented bone marrow engraftment of leukemic cells in OCI-AML2 xenograft mouse models without observable side effects.
Correction: Endoscopic submucosal dissection of poorly differentiated carcinoma mimicking adenoid-cystic carcinoma of the esophagus
Authors: Fabio De Vincentis, Roberta Maselli, Mario Brancaccio, Alessandro Mussetto
Journal: Endoscopy (2022)

Correction to: Endoscopic submucosal dissection of poorly differentiated carcinoma mimicking adenoid-cystic carcinoma of the esophagusEndoscopy eFirstDOI: 10.1055/a-1724-7162
Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma
Authors: Marta Alonso-Nocelo, Laura Ruiz-Cañas, Patricia Sancho, Kıvanç Görgülü, Sonia Alcalá, Coral Pedrero, Mireia Vallespinos, Juan Carlos López-Gil, Marina Ochando, Elena García-García, Sara Maria David Trabulo, Paola Martinelli, Patricia Sánchez-Tomero, Carmen Sánchez-Palomo, Patricia Gonzalez-Santamaría, Lourdes Yuste, Sonja Maria Wörmann, Derya Kabacaoğlu, Julie Earl, Alberto Martin, Fernando Salvador, Sandra Valle, Laura Martin-Hijano, Alfredo Carrato, Mert Erkan, Laura García-Bermejo, Patrick C Hermann, Hana Algül, Gema Moreno-Bueno, Christopher Heeschen, Francisco Portillo, Amparo Cano, Bruno Sainz
Journal: Gut (2022)

Objective The lysyl oxidase-like protein 2 (LOXL2) contributes to tumour progression and metastasis in different tumour entities, but its role in pancreatic ductal adenocarcinoma (PDAC) has not been evaluated in immunocompetent in vivo PDAC models. Design Towards this end, we used PDAC patient data sets, patient-derived xenograft in vivo and in vitro models, and four conditional genetically-engineered mouse models (GEMMS) to dissect the role of LOXL2 in PDAC. For GEMM-based studies, K-Ras +/LSL-G12D ; Trp53 LSL-R172H ; Pdx1-Cre mice (KPC) and the K-Ras +/LSL-G12D ; Pdx1-Cre mice (KC) were crossed with Loxl2 allele floxed mice ( Loxl2 Exon2 fl/fl ) or conditional Loxl2 overexpressing mice (R26 Loxl2 KI/KI ) to generate KPCL2 KO or KCL2 KO and KPCL2 KI or KCL2 KI mice, which were used to study overall survival; tumour incidence, burden and differentiation; metastases; epithelial to mesenchymal transition (EMT); stemness and extracellular collagen matrix (ECM) organisation. Results Using these PDAC mouse models, we show that while Loxl2 ablation had little effect on primary tumour development and growth, its loss significantly decreased metastasis and increased overall survival. We attribute this effect to non-cell autonomous factors, primarily ECM remodelling. Loxl2 overexpression, on the other hand, promoted primary and metastatic tumour growth and decreased overall survival, which could be linked to increased EMT and stemness. We also identified tumour-associated macrophage-secreted oncostatin M (OSM) as an inducer of LOXL2 expression, and show that targeting macrophages in vivo affects Osm and Loxl2 expression and collagen fibre alignment. Conclusion Taken together, our findings establish novel pathophysiological roles and functions for LOXL2 in PDAC, which could be potentially exploited to treat metastatic disease.
The Complicated Inadequacy of Race and Ethnicity Data
Authors: Barbara H. Chaiyachati, Michelle-Marie Peña, Diana Montoya-Williams
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
FDG PET/CT and Bone Scintigraphy in Desmoplastic Fibroma of the Bone
Authors: Jun Zhang, Shensheng Nian, Yushu Bai, Aisheng Dong
Journal: Clinical Nuclear Medicine (2022)

Abstract Desmoplastic fibroma is a very rare benign bone tumor with local aggressiveness. We describe imaging findings in 2 cases with desmoplastic fibroma of the bone. One case had a desmoplastic fibroma in the right distal femur, showing bone destruction with sclerotic margins and inhomogeneous FDG uptake. The other case had a desmoplastic fibroma in the left ninth rib, showing progressive peripheral enhancement and increased 99m Tc-MDP uptake.
A Sub-6 nm MnFe2O4-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy
Authors: Zan Dai, Qiaoyun Wang, Jie Tang, Rui Qu, Min Wu, Haoze Li, Yannan Yang, Xu Zhen, Chengzhong Yu
Journal: Biomaterials (2022)
Cancer stem-like cells evade CD8<sup>+</sup>CD103<sup>+</sup>tumor-resident memory T (T<sub>RM</sub>) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
Authors: Stéphanie Corgnac, Isabelle Damei, Gwendoline Gros, Aziza Caidi, Stéphane Terry, Salem Chouaib, Marc Deloger, Fathia Mami-Chouaib
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Cancer stem cells (CSC) define a population of rare malignant cells endowed with ‘stemness’ properties, such as self-renewing, multipotency and tumorigenicity. They are responsible for tumor initiation and progression, and could be associated with resistance to immunotherapies by negatively regulating antitumor immune response and acquiring molecular features enabling escape from CD8 T-cell immunity. However, the immunological hallmarks of human lung CSC and their potential interactions with resident memory T (T RM ) cells within the tumor microenvironment have not been investigated. Methods We generated a non-small cell lung cancer model, including CSC line and clones, and autologous CD8 + CD103 + T RM and CD8 + CD103 − non-T RM clones, to dissect out immune properties of CSC and their susceptibility to specific T-cell-mediated cytotoxic activity. Results Unlike their parental tumor cells, lung CSC are characterized by the initiation of an epithelial-to-mesenchymal transition program defined by upregulation of the SNAIL1 transcription factor and downregulation of phosphorylated-GSK-3β and cell surface E-cadherin. Acquisition of a CSC profile results in partial resistance to T RM -cell-mediated cytotoxicity, which correlates with decreased surface expression of the CD103 ligand E-cadherin and human leukocyte antigen-A2-neoepitope complexes. On the other hand, CSC gained expression of intercellular adhesion molecule (ICAM)-1 and thereby sensitivity to leukocyte function-associated antigen (LFA)-1-dependent non-T RM -cell-mediated killing. Cytotoxicity is inhibited by anti-ICAM-1 and anti-major histocompatibility complex class I neutralizing antibodies further emphasizing the role of LFA-1/ICAM-1 interaction in T-cell receptor-dependent lytic function. Conclusion Our data support the rational design of immunotherapeutic strategies targeting CSC to optimize their responsiveness to local CD8 + CD103 + T RM cells for more efficient anticancer treatments.
Pituitary Metastasis of Non–Small Cell Lung Cancer With High FDG Uptake on PET/CT Pituitary Metastasis of Non–Small Cell Lung Carcinoma
Authors: Coline Le Meur, Luca Campedel, Dris Kharroubi, Karim Amrane
Journal: Clinical Nuclear Medicine (2022)

Abstract Pituitary metastasis is a rare event, and the pituitary gland is an uncommonly involved location in patients with intracranial metastases as it accounts for only approximately 2% of malignant metastases. Here, the authors present the 18 F-FDG PET study of a very rare case of relapsed non–small cell lung cancer, locally and with 1 pituitary metastasis, in a 75-year-old White woman with asthenia and diabetes insipidus. 18 F-FDG PET and cerebral MRI were performed to guide the therapeutic strategy due to an atypical pituitary high FDG avidity.
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes
Authors: Hamed Kianmehr, Ping Zhang, Jing Luo, Jingchuan Guo, Meda E. Pavkov, Kai McKeever Bullard, Edward W. Gregg, Naykky Singh Ospina, Vivian Fonseca, Lizheng Shi, Hui Shao
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Improvements in control of factors associated with diabetes risk in the US have stalled and remain suboptimal. The benefit of continually improving goal achievement has not been evaluated to date. <h3>Objective</h3> To quantify potential gains in life expectancy (LE) among people with type 2 diabetes (T2D) associated with lowering glycated hemoglobin (HbA<sub>1c</sub>), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), and body mass index (BMI) toward optimal levels. <h3>Design, Setting, and Participants</h3> In this decision analytical model, the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes microsimulation model was calibrated to a nationally representative sample of adults with T2D from the National Health and Nutrition Examination Survey (2015-2016) using their linked short-term mortality data from the National Death Index. The model was then used to conduct the simulation experiment on the study population over a lifetime. Data were analyzed from January to October 2021. <h3>Exposure</h3> The study population was grouped into quartiles on the basis of levels of HbA<sub>1c</sub>, SBP, LDL-C, and BMI. LE gains associated with achieving better control were estimated by moving people with T2D from the current quartile of each biomarker to the lower quartiles. <h3>Main Outcomes and Measures</h3> Life expectancy. <h3>Results</h3> Among 421 individuals, 194 (46%) were women, and the mean (SD) age was 65.6 (8.9) years. Compared with a BMI of 41.4 (mean of the fourth quartile), lower BMIs of 24.3 (first), 28.6 (second), and 33.0 (third) were associated with 3.9, 2.9, and 2.0 additional life-years, respectively, in people with T2D. Compared with an SBP of 160.4 mm Hg (fourth), lower SBP levels of 114.1 mm Hg (first), 128.2 mm Hg (second), and 139.1 mm Hg (third) were associated with 1.9, 1.5, and 1.1 years gained in LE in people with T2D, respectively. A lower LDL-C level of 59 mg/dL (first), 84.0 mg/dL (second), and 107.0 mg/dL (third) were associated with 0.9, 0.7, and 0.5 years gain in LE, compared with LDL-C of 146.2 mg/dL (fourth). Reducing HbA<sub>1c </sub>from 9.9% (fourth) to 7.7% (third) was associated with 3.4 years gain in LE. However, a further reduction to 6.8% (second) was associated with only a mean of 0.5 years gain in LE, and from 6.8% to 5.9% (first) was not associated with LE benefit. Overall, reducing HbA<sub>1c</sub>from the fourth quartile to the first is associated with an LE gain of 3.8 years. <h3>Conclusions and Relevance</h3> These findings can be used by clinicians to motivate patients in achieving the recommended treatment goals and to help prioritize interventions and programs to improve diabetes care in the US.
Thapsigargin: key to new host-directed coronavirus antivirals?
Authors: Mohammed Samer Shaban, Christin Mayr-Buro, Johanna Meier-Soelch, Benadict Vincent Albert, M. Lienhard Schmitz, John Ziebuhr, Michael Kracht
Journal: Trends in Pharmacological Sciences (2022)

Despite the great success of vaccines that protect against RNA virus infections, and the development and clinical use of a limited number of RNA virus-specific drugs, there is still an urgent need for new classes of antiviral drugs against circulating or emerging RNA viruses. To date, it has proved difficult to efficiently suppress RNA virus replication by targeting host cell functions, and there are no approved drugs of this type. This opinion article discusses the recent discovery of a pronounced and sustained antiviral activity of the plant-derived natural compound thapsigargin against enveloped RNA viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A virus. Based on its mechanisms of action, thapsigargin represents a new prototype of compounds with multimodal host-directed antiviral activity.
Supramolecular Thermo‐Contracting Adhesive Hydrogel with Self‐Removability Simultaneously Enhancing Noninvasive Wound Closure and MRSA‐Infected Wound Healing
Authors: Rui Yu, Meng Li, Zhenlong Li, Guoying Pan, Yuqing Liang, Baolin Guo
Journal: Advanced Healthcare Materials (2022)

Conventional wound closure and dressing are two crucial, time-consuming but isolated principles in wound care. Even though tissue adhesive opens a new era for wound closure, the method and biomaterial that can simultaneously achieve noninvasive wound closure and promote wound healing are highly appreciated. Herein, a novel supramolecular poly(N-isopropylacrylamide) hybrid hydrogel dressing composed of quaternized chitosan-graft-β-cyclodextrin, adenine, and polypyrrole nanotubes via host-guest interaction and hydrogen bonds is developed. The hydrogel demonstrates thermal contraction of 47% remaining area after 2 h at 37 ℃ and tissue adhesion of 5.74 kPa, which are essential for noninvasive wound closure, and multiple mechanical and biological properties including suitable mechanical properties, self-healing, on-demand removal, antioxidant, hemostasis, and photothermal/intrinsic antibacterial activity (higher 99% killing ratio within 5 min after irradiation). In both full-thickness skin incision and excision wound models, the hydrogel reveals significant wound closure after 24 h post-surgery. In acute and methicillin-resistant Staphylococcus aureus-infected wound and photothermal/intrinsic antibacterial activity assays, wounds treated with the hydrogel demonstrate enhanced wound healing with rapid wound closure rate, mild inflammatory response, advanced angiogenesis, and well-arranged collagen fibers. Altogether, the results indicate the hydrogel is promising in synchronously noninvasive wound closure and enhanced wound healing.
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
Authors: Oren Auster, Uriah Finkel, Noa Dagan, Noam Barda, Alon Laufer, Ran D. Balicer, Shay Ben-Shachar
Journal: JAMA Network Open (2022)
Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment
Authors: Joanne Tze Chin Lim, Leng Gek Kwang, Nicholas Ching Wei Ho, Clarissa Chin Min Toh, Nathaniel Sheng Hua Too, Lissa Hooi, Touati Benoukraf, Pierce Kah-Hoe Chow, Yock Young Dan, Edward Kai-Hua Chow, Tan Boon Toh, Eliza Li Shan Fong
Journal: Biomaterials (2022)